{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:43:34Z","timestamp":1787755414889,"version":"build-2784847793"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.1093\/cid\/cix325","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T19:15:16Z","timestamp":1491851716000},"page":"510-513","source":"Crossref","is-referenced-by-count":30,"title":["Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation"],"prefix":"10.1093","volume":"65","author":[{"given":"Daniel P.","family":"Prestes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Arbona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Nevett-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M.","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"key":"key\n\t\t\t\t20170714113759_CIT0001","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","year":"2007","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20170714113759_CIT0002","first-page":"7","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170714113759_CIT0003","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","article-title":"Chronic myelogenous leukemia, version 1.2014","volume":"11","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"key\n\t\t\t\t20170714113759_CIT0004","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","year":"2015","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20170714113759_CIT0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bmt.1703899","article-title":"Bone marrow transplant in Ph+ALL patients","volume":"31","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170714113759_CIT0006","first-page":"1572","article-title":"Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome unrelated marrow transplantation for adult patients with poor-risk acute lymphoblast","volume":"97","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170714113759_CIT0007","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bbmt.2011.12.587","article-title":"Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20170714113759_CIT0008","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3109\/10428194.2014.994179","article-title":"Dasatinib-induced immunosuppression and recurrent respiratory tract infections","volume":"56","year":"2015","journal-title":"Leuk Lymphom"},{"key":"key\n\t\t\t\t20170714113759_CIT0009","first-page":"77","article-title":"Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy","volume":"8","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"key":"key\n\t\t\t\t20170714113759_CIT0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170714113759_CIT0011","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170714113759_CIT0012","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily","volume":"39","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"key\n\t\t\t\t20170714113759_CIT0013","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/10428190701671044","article-title":"Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825)","volume":"48","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20170714113759_CIT0014","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/648120","article-title":"The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation","volume":"49","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/3\/510\/18611985\/cix325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T20:26:19Z","timestamp":1503606379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cix325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,4,13]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix325","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}